Earnings analysis · 10-Q
IONS earnings analysis
Filed April 29, 2026 · Our reading of the company's report
The latest report
Ionis Pharmaceuticals reported solid Q1 2026 results with revenue of $246 million, surpassing expectations by $51 million. However, EPS showed a larger loss than projected at -$1.16, compared to an expectation of -$0.80.
Reported figures
- Earnings per share
- $-1.16
What stood out
-
Revenue Exceeds Projections
Total revenue reached $246 million, exceeding estimates by $51 million.
-
Improving Financial Position
The company shows a robust financial foundation supported by diverse revenue sources.
-
Independent Launches Ahead
Two independent launches are underway, positioning Ionis for future growth.
-
Positive Cash Flow Management
Despite losses, Ionis continues to maintain a strong cash position.
-
Multiple Upcoming Launches
Key upcoming medicines are anticipated to enhance future revenues.
-
Strong Product Pipeline
The company continues to advance several late-stage medicines.
What to watch
-
High Operating Expenses
Operational costs remain elevated, impacting overall profitability.
-
Dependence on Regulatory Approvals
The company’s growth hinges on successful regulatory approvals for new products.
-
Risk from Convertible Notes Maturity
Maturity of convertible notes poses a refinancing risk, especially amid market volatility.
Management's outlook
Outlook deferred to earnings press release / call.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.